FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
Within the KiCS study researchers found targetable mutations in more than half of the kids, but few actually received drugs based on those molecular markers.
Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.
Using baseline blood samples, researchers have identified an eight-gene expression signature to predict patient responses to Zytiga plus prednisone or Xtandi.
The company hopes the collaboration will allow it to home in on a molecularly defined population of patients likely to benefit from its targeted agent LP-184.
The signature may be useful for guiding treatment strategy based on patients' prognoses, and with further validation, may even be useful for predicting response to specific drugs.
As MacroGenics advances flotetuzumab through AML studies, it is working with researchers to refine the predictive ability of the gene expression signature.
A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.
